Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 01 2021 - 5:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 28, 2021
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
Bagsværd,
Denmark, 28 May 2021 – Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug
Administration (FDA) for the existing marketing authorisation for Ozempic®,
a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. The resubmission follows the Refusal to File
letter received by the FDA on 22 March 2021. The standard review time by the FDA is 10 months.
About
Novo Nordisk
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to
defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs
about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook,
Twitter, LinkedIn, YouTube.
Further
information
Media:
|
|
|
Mette
Kruse Danielsen
|
+45
3079 3883
|
mkd@novonordisk.com
|
Michael
Bachner (US)
|
+1
609 664 7308
|
mzyb@novonordisk.com
|
Investors:
|
|
|
Daniel
Muusmann Bohsen
|
+45
3075 2175
|
dabo@novonordisk.com
|
Valdemar
Borum Svarrer
|
+45
3079 0301
|
jvls@novonordisk.com
|
Ann
Søndermølle Rendbæk
|
+45
3075 2253
|
arnd@novonordisk.com
|
David
Heiberg Landsted
|
+45
3077 6915
|
dhel@novonordisk.com
|
Mark
Joseph Root (US)
|
+1
848 213 3219
|
mjhr@novonordisk.com
|
Novo
Nordisk A/S
Investor Relations
|
Novo
Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement
No 36 / 2021
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 28, 2021
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024